Peanut immunotherapy viewed from the BRIT Registry
No Thumbnail Available
Authors
Gourgey R.
Villa L.P.
Maslovskaya O.
Smith M.
Achunche S.
Baigel R.
Dawson T.
Kelly M.
Khan S.
Marriage D.
Check for full-text access
Issue Date
2025
Type
Article
Language
Keywords
Alternative Title
Abstract
Objectives: Peanut immunotherapy (PIT) was licensed for use in the UK in 2021 and NICE approved for England and Wales in 2022. BRIT is the national registry for allergen immunotherapy includes peanut immunotherapy as one of the treatment domains. Method(s): Patient participants consent in writing to join the registry and return patient-related outcome measures (PROM). Data were downloaded for analysis on January 15th 2025 and PIT participants compared with other allergen immunotherapy domains. Result(s): 103/3532 (3%) of registry participants were recruited for PIT. 95.1% (98/103) were children under 16 years old (cf 45.6% total registry), 76.7% (79) were of white ethnicity, 97% (100) were from England (cf 94% total registry). There were no PIT participants from Wales, Northern Ireland and Scotland. 52.4% (54) were NHS participants and 46.6% (48) from private practice (cf 4.1% whole registry). 33% of PIT participants had self-referred (cf 3% total registry). For PIT participants 44.7% (46) had rhinoconjunctivitis 30.1% (30) asthma, 27.2% (28) active eczema, and none had a current diagnosis/history of eosinophilic oesophagitis (EoE). As a method of peanut diagnosis food challenge was used in 17 participants, skin prick testing 78 participants Specific IgE 47 participants, and component resolved diagnostic specific IgE in 31. 101 participants were prescribed oral peanut immunotherapy with 64% (65) Palforzia (Aimmune), 28% (28) real world peanut and 1% (1) Nutlife (Cambridge). There was no reported new diagnosis of EoE, though 78/101 participants did not provide data to this question. Conclusion(s): PIT is a small part of the current BRIT registry. Participants are limited to England with a larger cohort of private practice and self-referring patients than in other registry domains. As PIT and other food immunotherapies become more common in the NHS, this data collection repository will be an important source of data for collecting real world evidence.
Description
Citation
Publisher
License
Journal
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology